M. Docteur Benoît FLACHAIRE
✨ Profil synthétique
IA · 01/05/2026Le Dr Benoît FLACHAIRE est un rhumatologue exerçant à Marseille. Ses publications sur PubMed portent sur les traitements anti-IL-23 et anti-IL-17, ainsi que sur la pharmacovigilance. Ces travaux suggèrent une implication dans la prise en charge de maladies rhumatismales chroniques.
Expertises présumées
- Polyarthrite rhumatoïde
- Spondylarthrite ankylosante
- Psoriasis
- Arthrite psoriasique
- Thérapies biologiques
- Pharmacovigilance en rhumatologie
- Maladies auto-immunes
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.
Diplômes
🎓 DES & spécialité ordinale
- DES Rhumatologie
- Rhumatologie (SM)
🎓 Diplômes
- DE Docteur en médecine
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
Bibliographie
Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study
2023ArticleDigestive and Liver Disease
Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison
2021ArticleRheumatology
Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy
2018ArticleRheumatology International
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Localisation des cabinets
Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.
Lieux de consultation
CABINET DU DR BenoIt FLACHAIRE
152 AVENUE DU PRADO, 13008 Marseille
LibéralAPHM HOPITAUX SUD SAINTE MARGUERITE
249 ET 270 — 270 Boulevard DE SAINTE MARGUERITE, 13274 Marseille 9e Arrondissement
☎ 0491380000HospitalierSERVICE DE SOINS SNCF
31 Boulevard VOLTAIRE, 13001 Marseille 1er Arrondissement
☎ 0495041016Hospitalier
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
Tarifs & secteur de conventionnement
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Vidéos & interventions (1)
Source YouTube · recherche par nom (homonymes possibles).
Top publications · les plus citées
- 1Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy
Rheumatology international · 2018
📚 26 citations🎯 RCR 1.62 - 2Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2023
- 3Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison
Rheumatology (Oxford, England) · 2021
Lire l'abstract Crossref ↓
Abstract Objectives To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA. Methods In this retrospective, national, multicentre cohort study, pts with PsA (CASPAR criteria or diagnosis confirmed by the rheumatologist) initiating UST or SEK with a follow-up ≥6 months were included from January 2011 to April 2019. The persistence between SEK and UST was assessed after considering the potential confounding factors by using pre-specified propensity-score methods. Causes of discontinuation and tolerance were also collected. Results A total of 406 pts were included: 245 with UST and 161 with SEK. The persistence rate was lower in the UST group compared with the SEK group [median persistence 9.4 vs 14.7 months; 26.4% vs 38.0% at 2 years; weighted hazard ratio (HR) = 1.42; 95% CI: 1.07, 1.92; P =0.015]. In subgroup analysis, the persistence rate of SEK associated with MTX was significantly higher than that of UST associated with MTX: HR = 2.20; 95% CI: 1.30, 3.51; P =0.001, in contrast to SEK vs UST monotherapy: HR = 1.06; 95% CI: 0.74, 1.53; P =0.75. Discontinuation due to inefficacy was reported in 91.7% (SEK) and 82.4% (UST) of pts. Discontinuation due to an adverse event was reported in 12.2% (SEK) and 7.7% (UST) of pts. Conclusion In this first study comparing UST and SEK, the persistence of SEK was higher than that of UST in PsA. In subgroup analysis, this difference was only found in association with MTX.
Publications scientifiques (3) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Anti-IL-232
▼
Anti-IL-232
▼- Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison
Rheumatology (Oxford, England) · 2021 · Comparative Study
Letarouilly JG, Flachaire B, Labadie C, Kyheng M, et al.
📚 12 cit.🔬→🩺 Translationnel - Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy
Rheumatology international · 2018 · Case Reports
Benzaquen M, Flachaire B, Rouby F, Berbis P, et al.
📚 26 cit.🎯 RCR 1.62
Anti-IL-171
▼
Anti-IL-171
▼- Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison
Rheumatology (Oxford, England) · 2021 · Comparative Study
Letarouilly JG, Flachaire B, Labadie C, Kyheng M, et al.
📚 12 cit.🔬→🩺 Translationnel
Pharmacovigilance1
▼
Pharmacovigilance1
▼- Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2023 · Multicenter Study
Guillo L, Flachaire B, Avouac J, Dong C, et al.
📚 18 cit.🎯 RCR 2.22